Literature DB >> 11385362

Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.

H C Hsu1, Y T Lee, H T Yeh, M F Chen.   

Abstract

Recent studies suggest that both oxidized very-low-density lipoprotein (VLDL) and oxidized high-density lipoprotein (HDL) may play a role in the pathogenesis of atherosclerosis. Gemfibrozil is widely used and is reported to decrease VLDL levels and increase HDL levels. The aim of this study was to investigate the effect of gemfibrozil on the chemical composition and oxidative susceptibility of VLDL and HDL and their relationship with atherosclerosis. Twenty patients with hypertriglyceridemia were treated with 300 mg gemfibrozil, 3 times daily, for 12 weeks. Venous blood samples were collected before treatment, at the end of treatment, and 4 weeks after the end of treatment. Gemfibrozil effectively lowered concentrations of plasma lipid, apolipoprotein (apo) B, and apo E. The lipid and protein content of VLDL were also decreased, but not by the same extent. The surface-to-core ratio and apo E/apo B ratio of VLDL particles were increased after gemfibrozil treatment. HDL(2) cholesteryl ester and HDL(3) apo A-II content were also increased. Gemfibrozil treatment lowered levels of lipid peroxides in both VLDL and HDL particles. The susceptibility of VLDL to oxidation was unchanged, whereas maximal peroxide production was decreased. The oxidative susceptibility of both HDL(2) and HDL(3) decreased with gemfibrozil treatment. These results indicate that after gemfibrozil treatment, VLDL and HDL particles in patients with hypertriglyceridemia are less atherogenic, which may explain why gemfibrozil treatment is beneficial in terms of coronary heart disease in hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385362     DOI: 10.1067/mlc.2001.114991

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  7 in total

1.  Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β.

Authors:  Malabendu Jana; Susanta Mondal; Frank J Gonzalez; Kalipada Pahan
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

2.  Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor β.

Authors:  Malabendu Jana; Kalipada Pahan
Journal:  Neurochem Res       Date:  2012-04-17       Impact factor: 3.996

3.  Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes.

Authors:  Kalipada Pahan; Malabendu Jana; Xiaojuan Liu; Bradley S Taylor; Charles Wood; Susan M Fischer
Journal:  J Biol Chem       Date:  2002-09-18       Impact factor: 5.157

4.  Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia.

Authors:  Malabendu Jana; Arundhati Jana; Xiaojuan Liu; Sankar Ghosh; Kalipada Pahan
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

5.  Banana prevents plasma oxidative stress in healthy individuals.

Authors:  Xuezhe Yin; Jishu Quan; Takemichi Kanazawa
Journal:  Plant Foods Hum Nutr       Date:  2008-02-09       Impact factor: 3.921

6.  CCR5 controls immune and metabolic functions during Toxoplasma gondii infection.

Authors:  Giuliano Bonfá; Luciana Benevides; Maria do Carmo Souza; Denise Morais Fonseca; Tiago Wilson Patriarca Mineo; Marcos Antônio Rossi; Neide Maria Silva; João Santana Silva; Cristina Ribeiro de Barros Cardoso
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

7.  Role of PPARs in Radiation-Induced Brain Injury.

Authors:  Sriram Ramanan; Weiling Zhao; David R Riddle; Mike E Robbins
Journal:  PPAR Res       Date:  2009-09-17       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.